Clinical Trial Update: Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. [Phase 3]

View source ↗

Summary

Durvalumab is being studied after chemoradiotherapy in a Phase 3 trial for limited-stage small cell lung cancer, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Carcinoma | Phase 3 | Status: RECRUITING